Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.71. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

The price of Bitcoin is reflective of a previous cycle, remaining near the golden Fibonacci retracement point and pointing to a future breakout. Bitcoin is exhibiting the reiteration of a price ...

There was an error while loading. Please reload this page. Gemma is a family of lightweight, state-of-the-art open models from Google, built from the same research ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion Pharma's AI-powered therapy reduces polyp growth in a rare disease trial Recursion Pharma , which uses artificial intelligence to discover new drug candidates, said on Monday its ...

Fibonacci sequences are sequences of numbers whose first two elements are 0, 1, and such that, starting from the third number, every element of the sequence is the sum of the previous two. They are of ...